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Organic analysis 216
SCFAs were determined by gas chromatography (GC) following N-(tert-butyldimethylsilyl)-217 N-methyltrifluoroacetamide derivitisation (Richardson, Calder, Stewart, & Smith, 1989 ). Each 218 sample was vortexed and 1 ml of sample or a standard solution transferred into a labelled 100 219 mm×16 mm glass tube (Fisher Scientific UK Ltd, Loughborough) with 50 μl of 2-ethylbutyric 220 acid (0.1 M internal standard solution), 500 μl concentrated HCl and 2 ml diethyl ether. All 221 samples were vortexed for 1 min and centrifuged at 2000 g for 10 min at room temperature 222 (SANYO MSE Mistral 3000i, Sanyo Gallenkap PLC, UK) twice (1 ml of diethyl ether added 223 in second extraction), aiming to completely extract the SCFAs. 400 µl of the pooled ether 224 extract and 50 µl N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) were 225 added into a GC screw-cap vial. Samples were heated at 80°C for 20 min and kept at room 226 temperature for 48h to enable further derivatisation. 227
A 5890 SERIES II Gas Chromatograph (Hewlett Packard, UK) using an Rtx-1 10m×0.18mm 228 column with a 0.20μm coating (Crossbond 100% dimethyl polysiloxane; Restek, 229 Buckinghamshire, UK) was used for SCFA analysis. Temperature of injector and detector was 230 275°C, with the column programmed from 63°C for 3 minutes to 190°C at 10°C min -1 and held 231 at 190°C for 3 minutes. Helium was the carrier gas (flow rate 1.2 ml min -1 ; head pressure 90 232 MPa). A split ratio of 100:1 was used. The SCFA external standard was run every 20 samples 233 to update the calibration as necessary. The SCFA external standard solution contained (mM): 234 sodium formate, 10; acetic acid, 30; propionic acid, 20; isobutyric acid, 5; n-butyric acid, 20; 235 iso-valeric acid, 5; n-valeric acid, 5; sodium lactate, 10; sodium succinate, 20. This standard 236 was treated the same as the samples and derivatised with added internal standard. Peak areas 237 of the standard solution, to which internal standard was added, were used to calculate the 238 response factors for each organic acid with respect to the internal standard. Response factor 239 and peak areas within samples were calibrated and calculated using Chemstation B.03. 
Viability assays 263
To determine the appropriate supernatant concentration, PBMC viability, at different 264 supernatant concentrations was determined using the trypan blue test. PBMC, adjusted to 2× 265 10 6 cells/ml, incubated in twenty-four-well plates in the presence of RPMI 1640 medium, pure 266 gut model medium supernatant, SS1V1, SS2V1 and SS3V1 fermentation supernatant from B-267 GOS and B. coagulans treated vessels, separately for 24 h at 37°C in an air-CO2 (19:1) 268 atmosphere incubator. The tested supernatant amount of each treatment was 1%, 1.5%, 2%, 269 3%, 4%, 5% and 10% (v/v) of 2ml (final working volume). At the end of the incubation, cell 270 numbers were counted using trypan blue test. According to viability results, only 1% (v/v) was 271 appropriate to use for different treatment supernatants. 272
Cytokine stimulation and detection 273
PBMCs were adjusted to yield 2×10 6 cells/ml. PBMCs were incubated in twenty-four-well 274 plates in the presence of 1 mg/ml lipopolysaccharide (LPS; Sigma Aldrich Co. Ltd., Spain), 1% 275 (v/v) pure gut model medium, 1 mg/ml LPS with 1% (v/v) pure gut medium or 1 mg/ml LPS 276 with 1% (v/v) supernatants from each steady state vessel of B-GOS and B. coagulans gut 277 models for 24 h at 37°C in an air-CO2 (19:1) atmosphere. At the end of the incubation, cell 278 culture supernatants were collected and stored at -20°C for later analysis of cytokine production. 279
Non-stimulated cultures were used as blank. 280
The production of IL-1β, IL-6, IL-8, IL-10 and TNF-α were measured using BD™ Cytometric 281 Results are presented as means ± SD. 289
Changes in specific bacterial groups, SCFA variation and cytokine production were assessed 290 between the three steady states using a one-way ANOVA. Significant differences were assessed 291 by post hoc Tukey HSD (Honestly Significant Difference) test. A value of P <0.05 indicates 292 there was a significant difference. In addition, for cytokine production, differences from LPS 293 control values were assessed using an independent t test. Furthermore, independent t test was 294 used to analyse the difference between B. coagulans and B-GOS treatments at SS3. A value of 295 P <0.05 was used to indicate a significant difference. 296 In the current study, the anti-inflammatory impact of prebiotic or probiotics may be related to 420 fermentation metabolites. In either prebiotic or probiotic supplemented in vitro gut models, 421 acetate was the predominant fatty acid, followed by butyrate and propionate (Figure 3 There was also no significant difference between LPS (LPS-stimulated PBMC) and gut+LPS (PBMC incubated with pure gut model medium and LPS). 
Results and Discussion
